Sarepta Therapeutics, Inc. vs Corcept Therapeutics Incorporated: Examining Key Revenue Metrics

Biotech Revenue Growth: Sarepta vs. Corcept from 2014-2023

__timestampCorcept Therapeutics IncorporatedSarepta Therapeutics, Inc.
Wednesday, January 1, 2014265510009757000
Thursday, January 1, 2015502860001253000
Friday, January 1, 2016813210005421000
Sunday, January 1, 2017159201000154584000
Monday, January 1, 2018251247000301034000
Tuesday, January 1, 2019306486000380833000
Wednesday, January 1, 2020353874000540099000
Friday, January 1, 2021365978000701887000
Saturday, January 1, 2022401858000933013000
Sunday, January 1, 20234823750001243336000
Loading chart...

Unleashing the power of data

A Tale of Two Biotechs: Revenue Growth from 2014 to 2023

In the competitive landscape of biotechnology, revenue growth is a key indicator of success. Over the past decade, Sarepta Therapeutics, Inc. and Corcept Therapeutics Incorporated have shown remarkable trajectories. Starting in 2014, Corcept's revenue was approximately $26.6 million, while Sarepta's was around $9.8 million. Fast forward to 2023, and Corcept's revenue has surged by over 1,700% to nearly $482 million. Meanwhile, Sarepta's revenue has skyrocketed by an astounding 12,600% to approximately $1.24 billion.

This growth highlights the dynamic nature of the biotech industry, where innovation and strategic investments can lead to exponential financial gains. Sarepta's impressive revenue increase reflects its successful product pipeline and market expansion, while Corcept's steady growth underscores its effective business strategies. As these companies continue to innovate, their financial trajectories offer valuable insights into the future of biotechnology.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025